What happened
Benign-by-design chemistry: Reinventing ligand-based drug design at the edge of AI
SourceElsevier BVpublicationBiotech
Benign-by-design chemistry: Reinventing ligand-based drug design at the edge of AI
Publication signal: Benign-by-design chemistry: Reinventing ligand-based drug design at the edge of AI
Factual summary
Why it matters
Recent source-backed research output for AISci Stage A browsing.
SourceElsevier BVLimitations
AISci rank score does not assess scientific quality or citation impact.
SourceElsevier BVLinked output
Benign-by-design chemistry: Reinventing ligand-based drug design at the edge of AIpaperPeople
No reviewed person relationship is attached to this event.
Organizations
No reviewed organization relationship is attached to this event.
Topics
Problems
No reviewed problem relationship is attached to this event.
Relationship evidence
Protein and Drug Design
Controlled AISci Stage A topic for Protein and Drug Design.
Benign-by-design chemistry: Reinventing ligand-based drug design at the edge of AI
Benign-by-design chemistry: Reinventing ligand-based drug design at the edge of AI
Timeline
- publicationBenign-by-design chemistry: Reinventing ligand-based drug design at the edge of AI